Keros Therapeutics, Inc. (KROS) Financial Statements
Keros Therapeutics, Inc. (KROS) reported trailing twelve-month revenue of $15.0M (down 93.6% year on year) and net income of -$83.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$48.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KROSKeros Therapeutics, Inc.Follow KROS — free
—
Price chart with a free account
- Market cap
- 223.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Revenue | 20.1 | 0.2 | 3.6 | 244.1 | 15.0 | |
| Research & development | 55.1 | 135.3 | 173.6 | 129.6 | 75.9 | |
| Operating income | -56.4 | -169.9 | -210.8 | 67.6 | -101.5 | |
| Pre-tax income | -56.7 | -153.0 | -187.1 | 91.9 | -86.1 | |
| Income tax | 2.0 | 0.0 | 0.3 | 4.9 | -2.9 | |
| Net income | -58.7 | -153.0 | -187.4 | 87.0 | -83.2 | |
| Diluted EPS ($) | -2.52 | -5.20 | -5.00 | 2.30 | -4.20 | |
| Diluted shares (mn) | 23.3 | 29.4 | 37.4 | 37.9 | — |
USD millions · SEC XBRL
Keros Therapeutics, Inc. — questions
- What is Keros Therapeutics, Inc.'s revenue?
- $15.0M over the twelve months to 2026-06-30, down 93.6% year on year, from its 10-Q and 10-K filings.
- What is Keros Therapeutics, Inc.'s net income?
- -$83.2M over the twelve months to 2026-06-30.
- What is Keros Therapeutics, Inc.'s free cash flow?
- -$48.5M over the twelve months to 2026-06-30.
- What are Keros Therapeutics, Inc.'s diluted earnings per share?
- $-4.20 over the twelve months to 2026-06-30.
Every figure on this page comes from Keros Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.